Broadens the previous indication for Jemperli plus chemotherapy to include patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumors.
Builds on previously announced primary endpoint, which showed up to 83% of adults achieved statistically significant improvement in MASH versus placebo.